Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.34 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.34 |
| ▸ | APP | P05067 | 1/20 | 0.32 |
| ▸ | PTGES | O14684 | 5/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.31 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.31 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.31 |
| ▸ | SYK | P43405 | 4/20 | 0.31 |
| ▸ | PIK3R2 | O00459 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12057969 | 0.93 | APP (0.37) | IRAK4PTPN11APPPTGESPTGS2 | |
| SCHEMBL12057769 | 0.91 | IRAK4 (0.34) | IRAK4PTPN11PTGESMAPK14SYK | |
| SCHEMBL12057767 | 0.90 | GPR6 (0.34) | IRAK4PTPN11SYK | |
| SCHEMBL12058054 | 0.88 | IRAK4 (0.37) | IRAK4PTGESPTGS2MKNK1SYK | |
| SCHEMBL12057674 | 0.87 | BTK (0.40) | SYK | |
| SCHEMBL12058133 | 0.84 | NAMPT (0.38) | IRAK4PTGESMKNK1SYK | |
| SCHEMBL12057970 | 0.84 | IRAK4 (0.33) | IRAK4PTGESPTGS2SYK | |
| SCHEMBL12057672 | 0.84 | PTGES (0.39) | IRAK4PTGESPTGS2MKNK1SYK | |
| SCHEMBL12058194 | 0.82 | IRAK4 (0.37) | IRAK4APPPTGESPTGS2MKNK1 | |
| SCHEMBL12057752 | 0.82 | MKNK1 (0.36) | IRAK4PTGESPTGS2MKNK1SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110318305-A1 | SUBSTITUTED PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS | MERCK SHARP & DOHME LLC | 2011-12-29 | — | — | US | disclosed |
| WO-2010022121-A1 | SUBSTITUTED PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS | SCHERING CORPORATION (US) | 2010-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110318305-A1 | SUBSTITUTED PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS | PNP, XDH, PNPO | IRAK4 706/4885PTPN11 368/4885APP 973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.